News
Zytiga Cleared Fast in Refractory CRPC, Can It Also Move to Earlier Use?
Zytiga Cleared Fast in Refractory CRPC, Can It Also Move to Earlier Use?
E Hayes
20110328
2011 Apr 28
The Pink Sheet Daily
Zytiga Cleared Fast in Refractory CRPC, Can It Also Move to Earlier Use?
The Pink Sheet Daily. 2011 Apr 28, E Hayes
FDA's speedy approval of Zytiga (abiraterone) on April 28 - two months before the PDUFA date - paves the way for a third new advanced prostate cancer drug to get to market in a year and heralds the coming of even more competition in the valuable space. An oral androgen biosynthesis inhibitor, abiraterone was cleared for use in combination with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC) after chemotherapy with docetaxel. Castration resistant prostate cancer...
Meet Our Experts
Meet our Advisory and Editorial Boards comprised of physician editors and world-renowned experts.
